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Abstract
Background: While several multigene signatures are available for predicting breast cancer prognosis, particularly in
early stage disease, effective molecular indicators are needed, especially for triple-negative carcinomas, to improve
treatments and predict diagnostic outcomes. The objective of this study was to identify transcriptional regulatory
networks to better understand mechanisms giving rise to breast cancer development and to incorporate this
information into a model for predicting clinical outcomes.
Methods: Gene expression profiles from 1097 breast cancer patients were retrieved from The Cancer Genome Atlas
(TCGA). Breast cancer-specific transcription regulatory information was identified by considering the binding site
information from ENCODE and the top co-expressed targets in TCGA using a nonlinear approach. We then used
this information to predict breast cancer patient survival outcome.
Result: We built a multiple regulator-based prediction model for breast cancer. This model was validated in more
than 5000 breast cancer patients from the Gene Expression Omnibus (GEO) databases. We demonstrated our
regulator model was significantly associated with clinical stage and that cell cycle and DNA replication related
pathways were significantly enriched in high regulator risk patients.
Conclusion: Our findings demonstrate that transcriptional regulator activities can predict patient survival. This
finding provides additional biological insights into the mechanisms of breast cancer progression.
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Background
Breast cancer is the most frequently diagnosed cancer
and the second leading cause of cancer deaths in women
worldwide [1]. In the United States, breast cancer
accounted for 30% of all new cancer cases and 14% of
cancer deaths for women in 2017, with an estimated
252,710 newly diagnosed cases and 40,610 deaths [2].
However, because of intertumoral and intratumor
heterogeneity, significant challenges exist in designing
effective treatment regimens and in predicting clinical
outcomes.
Currently, breast tumor classification is primarily
based on histopathologic features and the expression
of estrogen receptor (ER), progesterone receptor (PR)
and human epidermal growth factor receptor 2
(HER2) [3]. These subtypes differ with respect to
available receptor-targeted therapies, response to
treatment, clinical outcomes and risk of acquiring re-
sistance to therapy [4]. Hundreds of other biomarkers
have been reported in breast cancer for prognostic
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and therapeutic applications [5]. Over the past dec-
ade, multi-gene signatures have been developed for
breast cancer subtyping and risk stratification [6]. For
instance, the PAM50 gene signature measures the ex-
pression levels of 50 genes in breast cancer samples
to classify a tumor as one of five intrinsic subtypes
(luminal A, luminal B, HER2-enriched, basal-like and
normal like), and it has prognostic value in both
untreated and tamoxifen treated patient populations
[7, 8]. The MammaPrint assay categorized patients
into good or poor risk groups using 70 genes and has
been approved by the Food and Drug Administration
(FDA) to aid in predicting prognosis for breast cancer
patients with specific clinical characteristics [9, 10].
However, these gene-based risk models have certain
limitations and to date, there is no multigene test that
has been approved for recommending adjuvant treat-
ment for triple-negative (ER/PR/HER2-negative) breast
tumors. There remains a critical need for the devel-
opment of a robust model that can aid in effectively
predicting individual patient prognosis for hormone-
receptor-negative breast tumors that can convey add-
itional biological information from gene expression
profiles.
Transcriptional regulators, including the transcription
factors, cofactors, chromatin remodelers, histone modifi-
cation proteins and other DNA binding proteins, play
fundamental roles in many cellular processes including
response to extracellular and intracellular signals. By
binding to promoter regions of genes, transcription reg-
ulators are able to up- or down-regulate specific target
genes, thereby affecting many cellular activities. In re-
cent years, several studies have implemented machine-
learning methods in cancer prognostic biomarker devel-
opment. For example, a support vector machine (SVM)-
classifier has been used to construct a breast cancer
prognostic signature consisting of 10 microRNAs that
accurately predicted breast cancer stage [11]. Moreover,
a clustering-based method identified microRNA com-
binatorial biomarkers with high accuracy and efficiency
[12]. However, there are challenges with using machine-
learning methods with high-dimensional profiles [13].
We hypothesized that transforming gene expression
profiles into transcription regulator activity levels would
reduce the dimensionality while retaining the most use-
ful information from the gene expression profile during
feature selection and the model training process. Herein,
we built a transcription regulator-based model by min-
ing gene expression profiles from 1097 breast cancer
patients obtained from The Cancer Genome Atlas
(TCGA). We implemented a rank-based score function
to estimate the regulator activity levels to build the pre-
diction model. In addition, the predictive power of this
transcription regulator activity-based model was
validated on over 5000 breast cancer patient profiles in
the Gene Expression Omnibus (GEO) database. Gene
set enrichment analysis demonstrated that the transcrip-
tional regulator-based prognostic signature identified
key pathways involved in breast cancer development and
progression. Thus, transcription regulator activity
models are expected to provide new information that
could be used to develop new treatment strategies for
breast cancer.
Methods
Gene expression profiles
Breast cancer gene expression datasets and the corre-
sponding clinical data were downloaded from TCGA
and GEO databases. TCGA breast cancer RNA-
sequencing data (log2(norm_count + 1) normalized)
[14], including the corresponding clinical information,
were downloaded from UCSC Xena (http://xena.ucsc.
edu, version 2017-10-13) [15]. Validation microarray
datasets from 29 studies were downloaded from GEO
(Additional file 1: Table S1). For the Affymetrix micro-
array studies, raw data of microarray datasets were
downloaded in CEL format or processed soft matrix files
were used for datasets without CEL. After background
correction, the robust multi-array average (RMA)
method was used to normalize the Affymetrix micro-
array data [16]. For microarray studies using other plat-
forms, the series matrix files were downloaded from the
NCBI GEO website [17]. Probes were annotated to the
gene symbols, and multiple probes annotated to the
same gene were merged and mean values were calcu-
lated as the expression of the corresponding genes. The
clinical data were acquired from the respective literature
citations.
Chip-seq datasets from ENCODE
The transcriptional regulators and their target genes list
was retrieved from the ENCODE project via ChIPbase
V2 (http://rna.sysu.edu.cn/chipbase/) [18, 19]. The tran-
scription factor and chromatin remodeling factor regula-
tory domains were defined using the following settings:
1 kb upstream and downstream of the target gene tran-
scription start sites, union combination mode and all
motifs. The resulting lists were then limited to ENCODE
as the source. In total, 180 transcription factors or other
chromatin remodeling factor data were included and
together, are referred to as transcription regulators in
this study.
Survival analysis and statistical methods
The Cox proportional-hazards model was used to
select the candidate transcription regulator that
significantly associated with patients’ overall survival
[20, 21]. A multivariate Cox regression was performed
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to weight each of the selected potential transcription
regulators with an adapted coefficient. A transcrip-
tional regulator activity based risk score formula was
constructed by including statistically significant genes
weighted by their estimated multivariable Cox’s re-
gression adapted coefficients [22].
Risk score ¼
Xn
1
coefficient ið Þtranscription regulator ið Þ activity:
Patients were then divided into high-risk or low-risk
groups using the median risk score as the cutoff [23].
The Kaplan-Meier curve was used to compare the sur-
vival probabilities between the high-risk and low-risk
groups, and the log-rank test was adopted to test the
difference in survival rate between patients in the high-
and low-risk subgroups. A p-value less than 0.05 was
considered as statistically significant. The survival ana-
lyses were conducted with the survival package in the
statistical environment R (v3.5.1). Statistical computing
and visualization were conducted with R.
Gene set enrichment analysis was conducted with
GSEA software (http://www.broadinstitute.org/gsea) [24]
using the canonical pathways collection (version,
c2.cp.v6.2) [25] and a false discovery rate (FDR) value
less than 0.01 after performing 1000 permutations was
considered to be significant.
Results
Dataset and workflow for estimating transcription
regulator activities
RNA-seq profiles from 1097 primary breast cancer
patients were used as the training set. Transcription
regulator binding site information was extracted from
ChIP-seq data contained within ENCODE. This data in-
cluded 180 regulators and their gene targets. Addition-
ally, 29 breast cancer studies in GEO were used as a
validation set (Additional file 1: Table S1).
We estimated transcription regulator activity using
a method that was adapted from the single cell algo-
rithm SCENIC [26]. The workflow for obtaining this
estimate followed three steps as shown in Fig. 1.
Fig. 1 Workflow of the study. a. Estimation of transcription regulator activities workflow. Co-expression analysis of each regulator with all genes in
TCGA breast cancer cohort was performed using GRNBoost2 and regulator binding site information was retrieved from ENCODE (step 1). The
intersection of the top 5% of co-expressed genes with regulator target genes was identified (step 2) and used to calculate the regulator activity
with a rank-based approach (step 3). b. Overall workflow of the study. Abbreviations: TCGA, The Cancer Genome Atlas; GEO, Gene
Expression Omnibus
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Firstly, co-expression analysis for each of the 180
transcription regulators with all genes in the TCGA
breast cancer sets was conducted using GRNBoost2,
an efficient algorithm for regulatory network inference
using gradient boosting. Secondly, the intersection of
the top 5% of transcription regulator-gene pairs (i.e,
regulons) from GRNBoost2 [27] and genes from the
ENCODE ChIP-seq dataset produced the set of genes
considered to be the regulator targets that were
expressed in breast cancers. Thirdly, the activity of
each transcription regulator in each patient was mea-
sured with the rank based approach AUCell package
[28]. We calculated the enrichment of the identified
breast cancer specific regulator target as an area
under the recovery curve across the ranking of all
genes in a particular patient’s profile. The output is
the enrichment matrix of transcription regulator ac-
tivity for each patient; genes were ranked by their ex-
pression value and the cutoff parameter was set as
0.2 for both the training and testing sets. The rank-
based method enabled estimation of transcription
regulator activity at the individual patient level.
Transcription regulator activities correlated with breast
cancer subtypes
We postulated that transcription regulator activity
might be similar in breast cancers with similar gene
expression profiles. This would suggest that breast tu-
mors within the same molecular subtypes might have
similar transcription regulator profiles. To address this
question, we asked whether a correlation existed be-
tween commonly used molecular PAM50 subtypes and
the transcriptional regulator activity. Each transcrip-
tional regulator activity was calculated by the approach
described above. We then conducted an unsupervised
clustering with the regulator activity matrix. These re-
sults indicated that transcription regulator activity spe-
cifically identified the basal-like breast tumors (Fig. 2).
Transcriptional regulators that exhibited higher activ-
ities in the basal-like tumors compared to the other
breast cancer subtypes include BRF1, CTCFL, E2F1,
FOXM1, GTF2B, GTF3C2, HCFC1, KAT2A, MEF2C,
MYBL2, MYC, POLR3G and WRNIP1. These findings
are consistent with a previous report that FOXM1 func-
tions as a specific marker for triple negative breast
cancer [29]. In addition, previous studies have demon-
strated that triple-negative tumors exhibit elevated ex-
pression of MYC regulatory genes and increased
activity of the MYC pathway [30].
Transcriptional regulator activity was associated with
breast cancer prognosis
We next asked whether transcription regulator activity
would be useful in predicting breast cancer patient
Fig. 2 Correlation of transcription regulator activities with breast cancer subtypes. The distribution of transcription regulator activity and breast
cancer subtype with hormone receptor status and PAM50 molecular classification. The transcription regulator activity profile was generated by
unsupervised cluster analysis, in which the rows represented the regulator activities and the columns represented the samples. The transcription
regulator activity score varies between − 10 and + 10 as indicated by a gradient from green to red color
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prognosis. To address this question, we applied the Cox
proportional-hazards model to screen transcription reg-
ulators that correlated with the overall survival of breast
cancer patients. We found that fifteen transcription
regulator activities showed significant associations with
overall survival (Table 1). Among those 15 regulator ac-
tivities, four transcriptional regulators had hazard ratio
above 1 (CHD7, REST, TBP and THAP1), indicating
that elevated activities of these transcriptional regulators
were associated with poor prognosis. Eleven transcrip-
tion regulators (ATF3, BATF, ESR1, FOXA1, GTF2B,
IKZF1, IRF1, JUNB, KDM1A, MAX and STAT2) had a
hazard ratio less than 1, suggesting that higher activity
of these transcription regulators in breast tumors might
be beneficial for patient survival.
Transcriptional regulator model predicted breast cancer
overall survival
We then calculated risk scores for each breast cancer pa-
tient in the training set as described in the Methods sec-
tion. Patients were divided into low-risk and high-risk
groups using median risk score as the cut-off. The risk
scores distribution, survival status and transcription
regulator profiles for the TCGA training set are shown
Table 1 Transcriptional regulator activity associated with breast
cancer overall survival
Regulator log-rank p HR 95% CI p value
BATF 3.00E-06 0.45 (0.32–0.64) 5.26E-06
ESR1 0.002 0.60 (0.43–0.83) 0.0023
IRF1 0.0034 0.62 (0.44–0.85) 0.0037
THAP1 0.0099 1.53 (1.10–2.12) 0.0105
KDM1A 0.0158 0.67 (0.48–0.93) 0.0165
TBP 0.0167 1.49 (1.07–2.06) 0.0173
JUNB 0.0199 0.68 (0.49–0.94) 0.0206
ATF3 0.021 0.69 (0.50–0.95) 0.0218
CHD7 0.0236 1.45 (1.05–2.01) 0.0243
STAT2 0.032 0.70 (0.51–0.97) 0.0329
GTF2B 0.04 0.71 (0.52–0.99) 0.0409
IKZF1 0.0406 0.71 (0.52–0.99) 0.0416
FOXA1 0.0459 0.72 (0.52–1.00) 0.0469
MAX 0.046 0.72 (0.52–1.00) 0.0469
REST 0.0493 1.38 (1.00–1.91) 0.0502
*HR Hazard ratio, CI confidence interval
Fig. 3 Regulator based risk model of TCGA breast cancer patients. a The distribution of the significant regulator activities, patients’ survival status
and gene expression signature were analyzed in the TCGA breast cancer patients. (i) Hormone receptor status and PAM50 molecular classification
of breast cancer patients. (ii) Heatmap of the selected regulator activities profile. (iii) Patients overall survival status and time. Rows represent
genes, and columns represent patients. The red dashed line represents the risk score median cutoff dividing patients into low-risk and high-risk
groups. b Kaplan-Meier estimates of patient survival in high- and low-risk groups based on transcriptional regulator activities
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in Fig. 3a. Our results show that patients in the high-risk
group had significantly shorter overall survival time than
those in the low-risk group (log-rank P < 0.0001)
(Fig. 3b).
In addition, we found that more hormone receptor
negative (ER- and PR-negative) breast cancer patients
were assigned to the high-risk group. Likewise, the
basal-like and HER2-enriched breast cancer patients also
were in the high-risk group, which is consistent with the
clinical findings [31] that HER2-enriched and lumB sub-
types of breast cancer have a poor prognosis compared
with the lumA and normal-like breast cancers.
Validation of the transcription regulator model with
independent datasets
To test whether the high performance of the risk-
score model in the training dataset might have re-
sulted from overfitting, we evaluated the performance
of the transcription regulator activity model using in-
dependent breast cancer datasets from the GEO. Con-
sistent with the training set, patients with high risk
scores showed a clear trend of decreased survival rate
in 23 of 29 GEO studies (Fig. 4 a-f and Add-
itional file 1: Figure S1).
Notably, these independent validation GEO sets
used different gene-expression platforms, such as the
Affymetrix Human Genome U133A/B Array (Fig. 4 a-
c), Affymetrix Human Genome U133 Plus 2.0 Array
(Fig. 4 d and e) and the Illumina platform (Fig. 4f).
These data strongly suggest that patients assigned to
the high-risk group had significantly decreased 10-
year survival, compared with those patients in the low
risk groups. Taken together, we conclude that this
risk-score model shows robust performance across
datasets and platforms. We also tried to compare our
regulator model with an existing genomic classifica-
tion assay. MammaPrint risk for each patient in the
TCGA training set and the GEO validation breast
cancer set was measured with the genefu package in
R 3.6.0 [32]. The results are shown in Additional file 1:
Figure S3. The ROC curve showed that our regulator-
based model performed better than the MammaPrint
Fig. 4 Validation of the transcriptional regulator model with GEO datasets. Kaplan-Meier estimates of the survival of independent breast cancer
datasets using the regulator activity signature. a Kaplan-Meier curves of overall survival for a GSE25066, b GSE2034, c GSE3494, d GSE20685, e
GSE21653 and f GSE86166. The low-risk and high-risk groups of patients was determined on the basis of the median risk score for each validation
dataset. The tick marks on the Kaplan-Meier curves represent censored subjects. The statistically significant differences between the two curves
were determined by the two-sided log-rank test. The vertical red dashed line indicates the 10-year mark that was used for interpreting survival
difference between groups
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risk model in the two largest testing sets GSE25066
(Additional file 1: Figure S3A) and GSE20685
(Additional file 1: Figure S3B).
Association of transcription regulator model with clinical
and molecular features
To explore potential molecular mechanisms that might
contribute to the clinical association with the transcription
regulator activity-based model, we analyzed the correlation
between the regulator risk score and the cancer clinical
stage. We found the transcription regulator-based risk
score and the pathological stage of breast cancer patients
was correlated in both the training and validation sets (Fig. 5
a and b), where the one-way ANOVA p value reached
0.0001 for TCGA and p value was 4.8E-12 for GSE21653.
In addition, we performed Gene Set Enrichment
Analysis (GSEA) on the TCGA breast cancer cohort.
Compared with the patients assigned as low-risk, the
high-risk patient group showed that the top two
enriched pathways were cell cycle (Fig. 5c) and PLK
signaling (Fig. 5d), which both play critical roles in can-
cer initiation and development. These findings provide
evidence that the risk score can provide information
relevant to potential molecular mechanisms that might
be involved in tumor progression and survival outcome
in breast cancer patients.
Discussion
In this study, a transcriptional regulator-based model
was established for predicting the prognosis of breast
cancer. By transforming gene expression profiles to tran-
scription regulator activity levels, we demonstrated that
regulon activity can be used to explore breast cancer
gene expression data. After identifying that regulons
Fig. 5 Association of the transcription regulator-based risk score with pathological and molecular features. The regulator risk score is shown for
breast cancer stages in the TCGA cohort (a) and in a selected validation set GSE21653 (b). One-way ANOVA p values are provided. Cancer related
pathways that were significantly altered in patients with high regulator risk scores included cell cycle (c) and PLK1 signaling pathways (d).
Normalized enrichment score (NES) was used to evaluate the enrichment results
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significantly associated with breast cancer overall sur-
vival, we further constructed a multi-regulator activity-
based prediction model for breast cancer. The finding
from the training set was validated in different inde-
pendent GEO sets (> 3500 patients), which indicates that
the regulator activity-based model is robust.
Among the regulators that were used in the model,
several are known to play a role in breast cancer. The
chromatin remodeler CHD7 is one of the most com-
monly amplified CHD genes in breast cancer, and
mRNA expression levels of CHD7 are significantly up-
regulated in basal-like breast cancer [33]. The histone
demethylase KDM1A, which functions to repress and
activate transcription by mediating histone H3K4me1/2
and H3K9me1/2 demethylation, respectively, was re-
ported to be present at significantly lower levels in
breast cancer samples compared with normal tissues
[34, 35]. Consistent with the previous literature, we
found KDM1A was significantly lower in those patients
with worse survival. Silencing of THAP–zinc finger pro-
tein THAP1 inhibits endothelial G1/S cell-cycle progres-
sion [36]. High FOXA1 was associated with better breast
cancer specific survival among ER-positive breast cancer
[37]. Functional studies have demonstrated that JUNB
plays a pro-survival role in breast cancer cells in re-
sponse to a lethal dose of flavopiridol [38]. Low mRNA
expression of ESR1 is a determinant of tamoxifen resist-
ance in ER-positive breast cancer [39]. The majority of
the selected transcription regulators had been demon-
strated previously to be strongly associated with breast
cancer progression; therefore, differences in crucial regu-
lator activity between low- and high-risk groups may
provide new information for better understanding breast
tumor pathology and risk for recurrence.
We hypothesized that limiting a prognostic gene sig-
nature to transcription regulators would reduce the di-
mensionality of the expression profile during feature
selection and model training process. Additionally, we
predicted that such a transcription regulator activity pro-
file would be less susceptible to variability in the expres-
sion of individual genes and may thereby improve the
prognostic significance of tumor gene profiling. To the
best of our knowledge, a breast cancer prognostic signa-
ture with high prediction power has not yet been
constructed using only information provided by tran-
scription regulatory factors. Compared with other pub-
lished molecular signatures and panels for breast cancer,
this transcriptional regulator-based signature was highly
robust across different datasets and platforms with very
large-scale breast cancer samples, as the TCGA data was
from RNA-sequencing, while various microarray plat-
forms were used in GEO. The robustness of this model
arises primarily from two aspects. Firstly, each transcrip-
tional regulator activity was estimated using hundreds of
direct target genes by considering both co-expression
and ENCODE results, which produced a highly stable
model without perturbation due to the variability of sin-
gle gene expression levels. Secondly, the transcription
regulator activity estimation was based on the rank of
the absolute expression value of its target genes, which
enabled it to perform well across different gene expres-
sion platforms. In addition, the transcriptional regulator
activities were estimated in a tissue-specific manner,
which allows the regulator activity based prognostic risk
score to deliver additional biological information from
breast cancer mRNA expression profiles.
Limitations of this study include the assumption that
mRNA expression levels from the different platforms were
measured appropriately and reflect the actual mRNA
abundance of each gene. Secondly, the binding targets of
the regulators obtained from ENCODE were not specific
to breast cancer, so it is possible that a given regulator
might not bind to all of the same targets in breast tumors.
Thirdly, the cutoff for each dataset was determined separ-
ately based on the median risk score of the respective
dataset; however, we did find that the value of the risk
scores were in a similar range (− 12 to − 5).
Conclusion
In the present study, we built a robust model for pre-
dicting overall survival based on biologically relevant
transcriptional regulator information and further vali-
dated it using large cohorts of breast cancer patients.
The transcription regulator model should enhance our
understanding of breast cancer progression and guide
personalized treatment selection.
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